2 results
Approved WMOPending
Main study: to examine whether low dose GC therapy is more effective via the oral route compared to the parenteral route.Dose finding study (pilot study): to examine which oral GC dose is needed for a noticeable decrease in Erythrocyte Sedimentation…
Approved WMORecruiting
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).